Neoadjuvant therapy: Dawn of reducing the high post-surgery recurrence rate of hepatocellular carcinoma.

Combined locoregional and systemic antitumor treatment in neoadjuvant therapy As both local therapies (vascular intervention, radiotherapy) and systemic antitumor therapies (molecular targeted drug treatment, ICI treatment) have their own therapeutic advantages and different antitumor mechanisms, attempting to combine therapeutic approaches to explore potential synergistic effects to improve patient survival is currently an important trend in the treatment of HCC (Table 3 ).

also in 496 other papers